Conformationally-Locked N-Glycosides with Selective β-Glucosidase Inhibitory Activity: Identification of a New Non-Iminosugar-Type Pharmacological Chaperone for Gaucher Disease
- 4 July 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (15) , 6857-6865
Abstract
A series of conformationally locked N-glycosides having a cis-1,2-fused pyranose–1,3-oxazoline-2-thione structure and bearing different substituents at the exocyclic sulfur has been prepared. The polyhydroxylated bicyclic system was built in only three steps by treatment of the corresponding readily available 1,2-anhydrosugar with KSCN using TiO(TFA)2 as catalyst, followed by S-alkylation and acetyl deprotection. In vitro screening against several glycosidase enzymes showed highly specific inhibition of mammalian β-glucosidase with a marked dependence of the potency upon the nature of the exocyclic substituent. The most potent representative, bearing an S-(ω-hydroxyhexadecyl) substituent, was further assayed as inhibitor of the human lysosomal β-glucocerebrosidase and as pharmacological chaperone in Gaucher disease fibroblasts. Activity enhancements in N370S/N370S mutants analogous to those achieved with the reference compound ambroxol were attained with a more favorable chaperone/inhibitor balance.Keywords
This publication has 79 references indexed in Scilit:
- Differential Effects of an O-GlcNAcase Inhibitor on Tau PhosphorylationPLOS ONE, 2012
- Rapid Assembly of a Library of Lipophilic Iminosugars via the Thiol–Ene Reaction Yields Promising Pharmacological Chaperones for the Treatment of Gaucher DiseaseJournal of Medicinal Chemistry, 2012
- Metathesis access to monocyclic iminocyclitol-based therapeutic agentsBeilstein Journal of Organic Chemistry, 2011
- Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone ActivityJournal of Medicinal Chemistry, 2011
- Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher DiseaseJournal of Biological Chemistry, 2009
- Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinicsEMBO Molecular Medicine, 2009
- The Carbohydrate-Active EnZymes database (CAZy): an expert resource for GlycogenomicsNucleic Acids Research, 2008
- A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activityBiological Chemistry, 2007
- Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher diseaseProceedings of the National Academy of Sciences, 2007
- AcarboseDrugs, 1993